Procalcitonin and Pneumonia: Is it a useful marker?

被引：15

作者：

Christ-Crain M. ^{[1
]}

Müller B. ^{[1
]}

机构：

[1] University Hospitals, CH-4031 Basel

来源：

Current Infectious Disease Reports | 2007年 / 9卷 / 3期

关键词：

Procalcitonin; Lower Respiratory Tract Infection; Respir Crit; Pneumonia Severity Index; Antibiotic Stewardship;

D O I：

10.1007/s11908-007-0037-9

中图分类号：

学科分类号：

摘要：

An ideal biomarker for pneumonia should allow an early diagnosis and differential diagnosis from noninfectious conditions and should inform about the course and prognosis of the disease. Procalcitonin (PCT) covers these features better as compared to more commonly used biomarkers like Greactive protein or leukocyte count. PCT complements and improves the assessment of pneumonia based on careful patient history, dedicated physical examination, and appropriate cultures. Importantly, a PCT-based therapeutic strategy can safely and markedly reduce antibiotic courses in community-acquired pneumonia. However, as is the cast with all diagnostic surrogate markers, PCT can be increased in noninfectious conditions and may remain low in bacterial infections, especially localized infections. This stresses the importance of follow-up measurements, because PCT levels in these patients often show a gradual increase during follow-up. Although PCT is better than more common biomarkers for the prognosis of pneumonia and to predict survival and outcome, novel biomarkers show an even better prognostic accuracy. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：233 / 240

页数：7

共 60 条

[31]

Harbarth S., Holeckova K., Froidevaux C., Et al., Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis, Am J Respir Crit Care Med, 164, pp. 396-402, (2001)

[32]

Christ-Crain M., Stolz D., Bingisser R., Et al., Procalcitonin guidance of antibiotic therapy in co m mu nity- acquired pneumonia: A randomized trial, Am j Respir Crit Care Med, 174, pp. 84-93, (2006)

[33]

Carratala J., Fernandez-Sabe N., Ortega L., Et al., Outpatient care compared with hospitalization for community-acquired pneumonia: A randomized trial in low-risk patients, Ann Intern Med, 142, pp. 165-172, (2005)

[34]

Musher D.M., Alexandraki I., Graviss E.A., Et al., Bacteremic and nonbacteremic pneumococcal pneumonia. A prospective study, Medicine (Baltimore), 79, pp. 210-221, (2000)

[35]

Arancibia F., Bauer T.T., Ewig S., Et al., Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: Incidence, risk, and prognosis, Arch Intern Med, 162, pp. 1849-1858, (2002)

[36]

Genne D., Kaiser L., Kinge T.N., Lew D., Community-acquired pneumonia: Causes of treatment failure in patients enrolled in clinical trials, Clin Microbiol Infect, 9, pp. 949-954, (2003)

[37]

O'Donnell W.J., Kradin R.L., Evins A.E., Wittram C., Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 39-2004. A 52-year-old woman with recurrent episodes of atypical pneumonia, N Engl J Med, 351, pp. 2741-2749, (2004)

[38]

Moulin F., Raymond J., Lorrot M., Et al., Procalcitonin in children admitted to hospital with community acquired pneumonia, Arch Dis Child, 84, pp. 332-336, (2001)

[39]

Chastre J., Fagon J.Y., Ventilator-associated pneumonia, Am J Respir Crit Care Med, 165, pp. 867-903, (2002)

[40]

Duflo F., Debon R., Monneret G., Et al., Alveolar and serum procalcitonin: Diagnostic and prognostic value in ventilator-associated pneumonia, Anesthesiology, 96, pp. 74-79, (2002)

← 1 2 3 4 5 6 →